The toxic culture of Eli Lilly

Quote
Anonymous said:
Baaahhhaaaaaa!!!!!!! No way we can survive long enough to see enough decent drugs come out. They have done nothing but stuff a bunch of crap molecules into P1 trials to try to keep Wall Street buying our worthless stock. That's the reason that we used to launch so many drugs. We didn't have nearly as many molecules in the pipeline but they were drugs that we KNEW would most likely to make it out. Now they go on TV and brag about the number of drugs in our pipeline when they KNOW that most of them are total crap. It's like Madoff's Ponzi scheme. Sooner or later it's exposed and you can't run from it any more. The scam is up. What other pharma company has had 9 total losers in such a short amount of time? They knew all along these drugs were not going to make it. They just propped them up to keep the money coming in so that they could cash in. Of course our worthless BOD has just sat there and watched it happen. Because they are hand picked by our leaders as well. What has happened to this company is CRIMINAL. How are all the stock holders feeling now that it is obvious that they have been taken for a ride?
Click to expand...
You're absolutely correct john kept bragging about how many molecules in the pipeline his theory is easy to see through throw enough shit against the wall some of it has to stick
 






Anonymous said:
You're absolutely correct john kept bragging about how many molecules in the pipeline his theory is easy to see through throw enough shit against the wall some of it has to stick
Click to expand...

Problem is nothing is sticking. That's how bad these molecules are. Even the ones that might come out in the next 5 years are me too drugs that insurance won't pay top dollar for. It's pathetic.
 


















Anonymous said:
Patience Grasshopper......there's plenty of good drugs coming through development in biotech.

Will take a while to get to market but they will come good and save the company.
Click to expand...

The biotech pipeline? What are you smoking? You must have bought the line that clown Bumol and his incompetent managers have been spewing. What a joke! All the legitimate biotechs like Amgen, Biogen etc are laughing at us. AME is a joke, that has never delivered anything in the 10 years since we bought it. Same for the dopes in BioTDR in Indy.
Get a clue!!!
 






Anonymous said:
The biotech pipeline? What are you smoking? You must have bought the line that clown Bumol and his incompetent managers have been spewing. What a joke! All the legitimate biotechs like Amgen, Biogen etc are laughing at us. AME is a joke, that has never delivered anything in the 10 years since we bought it. Same for the dopes in BioTDR in Indy.
Get a clue!!!
Click to expand...

The stupid "you must be nice to everyone" philosophy has allowed dip-shirt people who blow amazing stories of fantasy to avoid challenges and continue to proceed up the corporate ladder. See Bumol, see Kershisnik, see Ware, see Brown, see Jan, see Azar, see Verhoeven...
 












Anonymous said:
The stupid "you must be nice to everyone" philosophy has allowed dip-shirt people who blow amazing stories of fantasy to avoid challenges and continue to proceed up the corporate ladder. See Bumol, see Kershisnik, see Ware, see Brown, see Jan, see Azar, see Verhoeven...
Click to expand...

What are you guys talking about? I heard TB say that "our biotech pipeline is the envy of the industry".....You mean this is not true?
 


















Anonymous said:
PeptoBUMol--the ultimate BioTaRD. A blight onto us all.
Click to expand...

I had the displeasure of working in the BioTDR group for 10 years, and I agree that there is nothing of significance in Lilly's biotech development portfolio. The best they have is me-too stuff like dulaglutide. Of particular note, it seems questionable that anything will come out of the Imclone pipeline. So, between AME and Imclone, biotech investment has been a boondoggle for Lilly so far.
 






Anonymous said:
I had the displeasure of working in the BioTDR group for 10 years, and I agree that there is nothing of significance in Lilly's biotech development portfolio. The best they have is me-too stuff like dulaglutide. Of particular note, it seems questionable that anything will come out of the Imclone pipeline. So, between AME and Imclone, biotech investment has been a boondoggle for Lilly so far.
Click to expand...

I was hoping that with ramucirumab there was at least some value in Imclone besides erbitux, but all the internal stuff like anti-BAFF, anti-IL17, anti-PCSK9 its all me-too and unfortunately years behind. eg.: PCSK9 projects at Amgen and Regeneron/Sanofi are finishing their Phase 3 data, while we are still in Phase 2. I just don't see how this portfolio will generate meaningful revenue anytime soon. AME was a also questionable investment, in my opinion.
 






Anonymous said:
I was hoping that with ramucirumab there was at least some value in Imclone besides erbitux, but all the internal stuff like anti-BAFF, anti-IL17, anti-PCSK9 its all me-too and unfortunately years behind. eg.: PCSK9 projects at Amgen and Regeneron/Sanofi are finishing their Phase 3 data, while we are still in Phase 2. I just don't see how this portfolio will generate meaningful revenue anytime soon. AME was a also questionable investment, in my opinion.
Click to expand...

All more profitable than Avid. Way to go John!
 


















Anonymous said:
I was hoping that with ramucirumab there was at least some value in Imclone besides erbitux, but all the internal stuff like anti-BAFF, anti-IL17, anti-PCSK9 its all me-too and unfortunately years behind. eg.: PCSK9 projects at Amgen and Regeneron/Sanofi are finishing their Phase 3 data, while we are still in Phase 2. I just don't see how this portfolio will generate meaningful revenue anytime soon. AME was a also questionable investment, in my opinion.
Click to expand...

Yeah, since ramucirumab failed the big breast cancer trial back in the fall, it's future value is in doubt. Also, I am pretty sure Erbitux sales have not flourished even close to Lilly's expectations when they bought Imclone. Part of this is due to several failures in trials for new cancer indications. In 2012 North American sales were only about $700M, which I think is split 50/50 between Lilly and BMS (foreign sales are under Merck KGaA).

So far, Imclone is looking like the biggest failure for JL since becoming LLY CEO.
 












Anonymous said:
Yeah, since ramucirumab failed the big breast cancer trial back in the fall, it's future value is in doubt. Also, I am pretty sure Erbitux sales have not flourished even close to Lilly's expectations when they bought Imclone. Part of this is due to several failures in trials for new cancer indications. In 2012 North American sales were only about $700M, which I think is split 50/50 between Lilly and BMS (foreign sales are under Merck KGaA).

So far, Imclone is looking like the biggest failure for JL since becoming LLY CEO.
Click to expand...

Dollar for dollar Avid is worse.
 












Anonymous said:
Dollar for dollar Avid is worse.
Click to expand...

Yes, Lilly has yet to make a dollar from it's purchase of Avid. But I believe the upfront purchase price was only $300M, with up to an additional $500M of milestone payments, contingent on sales of the amyloid imaging agent.

In contrast, they blew $6 Billion on Imclone, and all they have to show for it is about $300 million a year in Erbitux revenue and a few mABs in development that are of very questionable value.
 






Top Bottom
Back
Quote